Welcome to our dedicated page for Nanoviricides news (Ticker: NNVC), a resource for investors and traders seeking the latest updates and insights on Nanoviricides stock.
NanoViricides, Inc. develops clinical-stage antiviral therapeutics based on its nanoviricide technology and host-mimetic nanomedicine approach. Company news centers on NV-387, its lead broad-spectrum antiviral candidate, including clinical development for MPox, respiratory viral infections, measles and other viral diseases, as well as manufacturing updates for clinical product forms such as NV-387 Oral Gummies.
Recurring updates also cover FDA orphan-drug designation activity, rare-disease regulatory strategy, investor-conference participation and the company’s relationship with TheraCour Pharma for antiviral drug development technology. The news flow is focused on antiviral pipeline progress, regulatory designations and disease-area positioning rather than commercial product sales.
NanoViricides (NYSE:NNVC) announced that its drug candidate NV-387 could be crucial in fighting the increasing global measles cases. The drug has shown effectiveness against measles in animal studies and completed Phase I trials with no adverse events. NV-387 qualifies for Orphan Drug Designation and may be eligible for Fast Track designation, potentially accelerating its approval process.
The company highlighted concerning measles statistics: 1,319 confirmed cases in the USA, 3,800 cases in Canada, and over 127,350 cases in the European Region in 2024. NV-387 addresses an unmet medical need, as there are currently no approved drugs for measles treatment, while vaccination rates struggle to maintain the required 95% coverage for herd immunity.
NanoViricides (NYSE:NNVC) has detailed the significant market potential of its broad-spectrum antiviral drug NV-387, which has shown effectiveness against multiple viruses including Influenza, Coronaviruses, RSV, MPox, and Measles. The company is advancing toward a Phase II clinical trial for MPox treatment, where NV-387 could become the first approved drug for this indication.
The drug's potential extends to pandemic preparedness, with possible effectiveness against Ebola/Marburg and Hendra/Nipah viruses. The company plans to pursue orphan drug status for several indications and may be eligible for Priority Review Vouchers worth $150-250 million each. NV-387's unique mechanism mimics HSPG, a cell-side molecule that over 90% of human pathogenic viruses bind to, making viral escape unlikely.
NanoViricides (NYSE Amer: NNVC) has achieved a significant breakthrough in developing NV-387, potentially the first-ever drug treatment for Measles. In a humanized animal model study, NV-387 demonstrated strong effectiveness, increasing survival time by 130% (17 days vs. 7.4 days in untreated animals) with no toxicity signs.
The broad-spectrum antiviral drug works by acting as a cell decoy, targeting 90-95% of human pathogenic viruses that require sulfated proteoglycan features. The study utilized specially modified mice bearing the human CD150/SLAM protein, necessary for measles infection. This development is particularly significant as global measles cases rise and vaccination rates decline, especially in industrialized nations.
NanoViricides (NYSE:NNVC) has responded to WHO's extension of the MPox Public Health Emergency status by highlighting the development of their drug candidate NV-387. The company is preparing for Phase II clinical trials of NV-387 for MPox treatment, following successful Phase I safety results where the drug showed no adverse events and demonstrated oral availability.
Unlike current treatments Tecovirimat and Brincidofovir, which have shown limitations and safety concerns, NV-387 employs a unique host-mimetic nanomedicine technology that viruses reportedly cannot escape. The drug achieved a No-Observed-Adverse-Event Level at 1,200 mg/kg in animal studies and is formulated as oral gummies suitable for MPox patients with oral lesions.
The company aims to target a multi-billion-dollar global market for poxvirus bioterrorism preparedness, particularly focusing on the US Strategic National Stockpile market upon successful Phase II trials.
NanoViricides (NYSE:NNVC) has nearly completed the design of an adaptive clinical trial protocol for testing NV-387, their novel broad-spectrum antiviral drug, for treating MPox Virus Clade Ia and Ib infections. The trial will involve approximately 80 patients across two phases (IIa and IIb) in the Democratic Republic of Congo.
The Phase IIa will include 20 patients (10 in treatment arm, 10 in control), while Phase IIb will involve 60 patients in a 2:1 randomization (40 treatment, 20 control). The study will use "NV-387 Oral Gummies," designed specifically for MPox patients who have difficulty swallowing due to mucosal lesions.
If successful, NV-387 would be the first effective drug for MPox treatment in human clinical trials. The company plans to pursue regulatory approvals in Africa, USA, and EU, with potential for Orphan Drug Designation in the USA. The market opportunity is significant, as demonstrated by competitor SIGA's Tecovirimat generating over $600 million in US government sales through December 2024.
NanoViricides (NYSE Amer.:NNVC) has announced plans to advance its lead drug candidate NV-387 into Phase II clinical trials, initially focusing on MPox treatment. The company has already secured a Clinical Trial Site in the Democratic Republic of Congo (DRC) and is finalizing the trial protocol.
The strategic decision to prioritize MPox is driven by several factors: the ongoing epidemic in Africa enabling timely patient recruitment, lower clinical trial costs compared to US/Europe trials, and potential inclusion in the US Strategic National Stockpile (SNS). The company notes that current approved drugs for smallpox treatment, tecovirimat (Tpoxx) and brincidofovir (Tembexa), have shown limitations in MPox treatment.
NanoViricides has developed "NV-387 Oral Gummies" as the drug delivery format, specifically designed for MPox patients who may have difficulty swallowing due to mucosal lesions. The drug substance manufacture is substantially completed at the company's facility, with drug product manufacturing in progress.
NV-387's unique host-mimetic mechanism makes it potentially effective against various viruses while being difficult for viruses to develop resistance, positioning it as a potentially revolutionary treatment comparable to penicillin's impact on bacterial infections.